As Per the Report, the Size of the Middle East & Africa Lidocaine Ointment Market was valued at USD 68.34 Million in 2021 and is poised to reach USD 93.48 Million by 2026, to grow at a CAGR of 6.47% during the forecast period 2021 to 2026.
Lidocaine is a medicinal drug used to numb tissues. It is also known as xylocaine and lignocaine. Lidocaine blocks sodium channels and thus local neurons cannot signal the brain. It is used to relieve pain and irritation caused due to insect bites, minor cuts, sore mouth and sun burn, etc.
The significant drivers are increasing use of lidocaine ointment in cosmetic industry for pain relief and growing demand for lidocaine ointment as an anti-itching and pain relief medicine for insect bites, burns, skin scrape and minor cuts etc. Increasing R&D, rise in disposable income and growing awareness is also expected to drive the market over the forecast period. Strict regulations regarding safety and efficacy of the lidocaine ointment are major restraints limiting this industry.
This research report on the Middle East & Africa Lidocaine Ointment Market segmented and sub-segmented into the following categories
By Formulation:
By Application:
By Country:
On the basis of region, the Middle East and Africa have an untapped market and key players are slowly expanding to this region which is the main reason for the growth of market in this region.
Key Market Companies dominating the Middle East & Africa Lidocaine Ointment Market Profiled in the Report are AstraZeneca Plc., Glenmark Pharmaceuticals, Teligent, Inc., Proficient Rx LP, ., Septodont Healthcare India Pvt. Ltd., Gemini Pharmaceuticals, Amneal Pharmaceuticals LLC, Taro Pharmaceuticals U.S.A. Inc., Novocol Inc. and Centura Pharmaceuticals, Inc.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Formulation
5.1.1 Introduction
5.1.2 Internal Use
5.1.3 Topical Use
5.1.4 Y-o-Y Growth Analysis, By Formulation
5.1.5 Market Attractiveness Analysis, By Formulation
5.1.6 Market Share Analysis, By Formulation
5.2 Application
5.2.1 Introduction
5.2.2 Cosmetics
5.2.3 Medical
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Application
5.2.6 Market Attractiveness Analysis, By Application
5.2.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Formulation
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Formulation
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Formulation
6.1.5.3 By Application
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AstraZeneca Plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Centura Pharmaceuticals, Inc.
8.3 Amneal Pharmaceuticals LLC
8.4 Gemini Pharmaceuticals, Inc.
8.5 Glenmark Pharmaceuticals
8.6 Novocol Inc.
8.7 Proficient Rx LP
8.8 Septodont Healthcare India Pvt. Ltd.
8.9 Taro Pharmaceuticals U.S.A., Inc.
8.10 Teligent, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
